

PTO/SB/08b (7-09)

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/528,496		
		Filing Date	December 22, 2005		
		First Named Inventor	John D. Lambris		
		Art Unit	1654		
		Examiner Name	Maury A. Audet		
Sheet	1	of	2	Attorney Docket Number	34092-001 [P2942]

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/M.A./		BEELEY, N., "Pedidomimetics and small-molecular drug design: towards improved bioavailability and in vivo stability", Trends Biotechnol., Vol. 12, pp. 213-216 (1994).			
		DENNIS, M.S., et al., "Albumin binding as a general strategy for improving pharmacokinetics of proteins", J. Biol. Chem., Vol. 277, pp. 35035-35043 (2002)			
		HRUBY, V.J., "Conformational and topographical considerations in the design of biologically active peptides", Biopolymers, Vol. 33, pp. 1073-1082 (1993)			
		KOZLOWSKI, A., et al., "Development of pegylated interferons for the treatment of chronic hepatitis", BioDrugs, Vol.15, pp. 419-429 (2001)			
		SPRUCE, L., et al., "Chemical synthesis of small complement proteins and protein modules", International Immunopharmacology, Vol. 2, pp. 1320-1321 (2002)			
		VERONESE, F.M., "Peptide and protein PEGylation: a review of problems and solutions", Biomaterials, Vol. 22, pp. 405-417 (2001)			
		WANG, Y., et al., "Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a ...", Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 8563-8568 (1996)			
		ZHAO, B., et al., "A paradigm for drug discovery using a conformation from the crystal structure of a presentation scaffold", Nat. Struct. Biol., Vol. 2, pp. 1131-1137 (1995)			
↓		Non-Final Office Action in application No. 11/605,182, mailed June 30, 2009			
/M.A./		Final Office Action in application No. 11/605,182, mailed March 3, 2010			

Examiner Signature	/Maury Audet/	Date Considered	03/13/2011
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.A./

РТ0/СВ/08б (07-09)

Approved for use through 07/31/2012 OMB 0851-0031

U S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/528,496
				Filing Date	December 22, 2005
				First Named Inventor	John D. Lambris
				Art Unit	1654
				Examiner Name	Maury A. Audet
Sheet	2	of	2	Attorney Docket Number	
34092-001 [P2942]					

NON-PATENT LITERATURE DOCUMENTS

Examiner Signature	/Maury Audet/	Date Considered	03/13/2011
--------------------	---------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique diastem designation option(s). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.10. This collection is estimated to take 2 hours to complete, including gathering, preparing and maintaining the data for the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing it, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.A./